Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 42

1.

Discovery of a novel aminopyrazine series as selective PI3Kα inhibitors.

Barlaam B, Cosulich S, Fitzek M, Germain H, Green S, Hanson LL, Harris CS, Hancox U, Hudson K, Lambert-van der Brempt C, Lamorlette M, Magnien F, Ouvry G, Page K, Ruston L, Ward L, Delouvrié B.

Bioorg Med Chem Lett. 2017 Jul 1;27(13):3030-3035. doi: 10.1016/j.bmcl.2017.05.028. Epub 2017 May 10.

PMID:
28526367
2.

Discovery of a series of 8-(1-phenylpyrrolidin-2-yl)-6-carboxamide-2-morpholino-4H-chromen-4-one as PI3Kβ/δ inhibitors for the treatment of PTEN-deficient tumours.

Barlaam B, Cosulich S, Degorce S, Ellston R, Fitzek M, Green S, Hancox U, Lambert-van der Brempt C, Lohmann JJ, Maudet M, Morgentin R, Plé P, Ward L, Warin N.

Bioorg Med Chem Lett. 2017 May 1;27(9):1949-1954. doi: 10.1016/j.bmcl.2017.03.027. Epub 2017 Mar 14.

PMID:
28347666
3.

Discovery of a series of 8-(2,3-dihydro-1,4-benzoxazin-4-ylmethyl)-2-morpholino-4-oxo-chromene-6-carboxamides as PI3Kβ/δ inhibitors for the treatment of PTEN-deficient tumours.

Barlaam B, Cosulich S, Degorce S, Fitzek M, Green S, Hancox U, Lambert-van der Brempt C, Lohmann JJ, Maudet M, Morgentin R, Péru A, Plé P, Saleh T, Ward L, Warin N.

Bioorg Med Chem Lett. 2016 May 1;26(9):2318-23. doi: 10.1016/j.bmcl.2016.03.034. Epub 2016 Mar 11.

PMID:
26996374
4.

Discovery of 1-(4-(5-(5-amino-6-(5-tert-butyl-1,3,4-oxadiazol-2-yl)pyrazin-2-yl)-1-ethyl-1,2,4-triazol-3-yl)piperidin-1-yl)-3-hydroxypropan-1-one (AZD8835): A potent and selective inhibitor of PI3Kα and PI3Kδ for the treatment of cancers.

Barlaam B, Cosulich S, Delouvrié B, Ellston R, Fitzek M, Germain H, Green S, Hancox U, Harris CS, Hudson K, Lambert-van der Brempt C, Lebraud H, Magnien F, Lamorlette M, Le Griffon A, Morgentin R, Ouvry G, Page K, Pasquet G, Polanska U, Ruston L, Saleh T, Vautier M, Ward L.

Bioorg Med Chem Lett. 2015 Nov 15;25(22):5155-62. doi: 10.1016/j.bmcl.2015.10.002. Epub 2015 Oct 9.

PMID:
26475521
5.

Design of selective PI3Kα inhibitors starting from a promiscuous pan kinase scaffold.

Barlaam B, Cosulich S, Fitzek M, Green S, Harris CS, Hudson K, Lambert-van der Brempt C, Ouvry G, Page K, Ruston L, Ward L, Delouvrié B.

Bioorg Med Chem Lett. 2015 Jul 1;25(13):2679-85. doi: 10.1016/j.bmcl.2015.04.084. Epub 2015 Apr 29.

PMID:
25980912
6.

Overcoming obstacles in the implementation of factorial design for assay optimization.

Shaw R, Fitzek M, Mouchet E, Walker G, Jarvis P.

Assay Drug Dev Technol. 2015 Mar;13(2):88-93. doi: 10.1089/adt.2014.612. Epub 2015 Feb 24.

PMID:
25710279
7.

Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3Kβ and PI3Kδ for the treatment of PTEN-deficient cancers.

Barlaam B, Cosulich S, Degorce S, Fitzek M, Green S, Hancox U, Lambert-van der Brempt C, Lohmann JJ, Maudet M, Morgentin R, Pasquet MJ, Péru A, Plé P, Saleh T, Vautier M, Walker M, Ward L, Warin N.

J Med Chem. 2015 Jan 22;58(2):943-62. doi: 10.1021/jm501629p. Epub 2015 Jan 7.

PMID:
25514658
8.

Inhibition of PI3Kβ signaling with AZD8186 inhibits growth of PTEN-deficient breast and prostate tumors alone and in combination with docetaxel.

Hancox U, Cosulich S, Hanson L, Trigwell C, Lenaghan C, Ellston R, Dry H, Crafter C, Barlaam B, Fitzek M, Smith PD, Ogilvie D, D'Cruz C, Castriotta L, Wedge SR, Ward L, Powell S, Lawson M, Davies BR, Harrington EA, Foster E, Cumberbatch M, Green S, Barry ST.

Mol Cancer Ther. 2015 Jan;14(1):48-58. doi: 10.1158/1535-7163.MCT-14-0406. Epub 2014 Nov 14.

9.

Discovery of 9-(1-anilinoethyl)-2-morpholino-4-oxo-pyrido[1,2-a]pyrimidine-7-carboxamides as PI3Kβ/δ inhibitors for the treatment of PTEN-deficient tumours.

Barlaam B, Cosulich S, Degorce S, Fitzek M, Giordanetto F, Green S, Inghardt T, Hennequin L, Hancox U, Lambert-van der Brempt C, Morgentin R, Pass S, Plé P, Saleh T, Ward L.

Bioorg Med Chem Lett. 2014 Aug 15;24(16):3928-35. doi: 10.1016/j.bmcl.2014.06.040. Epub 2014 Jun 21.

PMID:
24992874
10.

Utilization of proton therapy: evidence-based, market-driven, or something in-between?

Dvorak T, Fitzek MM, Wazer DE.

Am J Clin Oncol. 2013 Apr;36(2):192-6. doi: 10.1097/COC.0b013e3182438d92.

PMID:
22391432
11.

Microdosimetric measurements for neutron-absorbed dose determination during proton therapy.

Pérez-Andújar A, Deluca PM Jr, Thornton AF, Fitzek M, Hecksel D, Farr J.

Radiat Prot Dosimetry. 2012 Aug;151(2):365-73. doi: 10.1093/rpd/ncs002. Epub 2012 Feb 14.

12.

Discovery of novel imidazo[1,2-a]pyridines as inhibitors of the insulin-like growth factor-1 receptor tyrosine kinase.

Ducray R, Simpson I, Jung FH, Nissink JW, Kenny PW, Fitzek M, Walker GE, Ward LT, Hudson K.

Bioorg Med Chem Lett. 2011 Aug 15;21(16):4698-701. doi: 10.1016/j.bmcl.2011.06.093. Epub 2011 Jun 29.

PMID:
21775140
13.

Proton therapy.

McDonald MW, Fitzek MM.

Curr Probl Cancer. 2010 Jul-Aug;34(4):257-96. doi: 10.1016/j.currproblcancer.2010.04.008. No abstract available.

PMID:
20647112
15.

Water equivalent thickness values of materials used in beams of protons, helium, carbon and iron ions.

Zhang R, Taddei PJ, Fitzek MM, Newhauser WD.

Phys Med Biol. 2010 May 7;55(9):2481-93. doi: 10.1088/0031-9155/55/9/004. Epub 2010 Apr 6.

16.

G2-phase chromosomal radiosensitivity of primary fibroblasts from hereditary retinoblastoma family members and some apparently normal controls.

Wilson PF, Nagasawa H, Fitzek MM, Little JB, Bedford JS.

Radiat Res. 2010 Jan;173(1):62-70. doi: 10.1667/RR1943.1.

17.

Retreatment of trigeminal neuralgia with Gamma Knife radiosurgery: is there an appropriate cumulative dose? Clinical article.

Dvorak T, Finn A, Price LL, Mignano JE, Fitzek MM, Wu JK, Yao KC.

J Neurosurg. 2009 Aug;111(2):359-64. doi: 10.3171/2008.11.JNS08770. Review.

PMID:
19326978
18.

Perineural invasion of cutaneous squamous cell carcinoma and basal cell carcinoma: raising awareness and optimizing management.

Geist DE, Garcia-Moliner M, Fitzek MM, Cho H, Rogers GS.

Dermatol Surg. 2008 Dec;34(12):1642-51. doi: 10.1111/j.1524-4725.2008.34341.x. Epub 2008 Oct 13.

PMID:
19018830
19.

Discovery of imidazole vinyl pyrimidines as a novel class of kinase inhibitors which inhibit Tie-2 and are orally bioavailable.

Buttar D, Edge M, Emery SC, Fitzek M, Forder C, Griffen A, Hayter B, Hayward CF, Hopcroft PJ, Luke RW, Page K, Stawpert J, Wright A.

Bioorg Med Chem Lett. 2008 Aug 15;18(16):4723-6. doi: 10.1016/j.bmcl.2008.06.106. Epub 2008 Jul 23.

PMID:
18676144
20.
21.

Multi-modality imaging of uveal melanomas using combined PET/CT, high-resolution PET and MR imaging.

Beyer T, Pietrzyk U, Knoess C, Vollmar S, Wienhard K, Kracht L, Bockisch A, Maderwald S, Kühl H, Fitzek M.

Nuklearmedizin. 2008;47(2):73-9.

PMID:
18392316
22.

Dosimetric impact of tantalum markers used in the treatment of uveal melanoma with proton beam therapy.

Newhauser WD, Koch NC, Fontenot JD, Rosenthal SJ, S Gombos D, Fitzek MM, Mohan R.

Phys Med Biol. 2007 Jul 7;52(13):3979-90. Epub 2007 Jun 6.

PMID:
17664589
23.

A defect in DNA double strand break processing in cells from unaffected parents of retinoblastoma patients and other apparently normal humans.

Kato TA, Wilson PF, Nagasawa H, Fitzek MM, Weil MM, Little JB, Bedford JS.

DNA Repair (Amst). 2007 Jun 1;6(6):818-29. Epub 2007 Mar 6.

PMID:
17339135
25.

Visual outcome of accelerated fractionated radiation for advanced sinonasal malignancies employing photons/protons.

Weber DC, Chan AW, Lessell S, McIntyre JF, Goldberg SI, Bussiere MR, Fitzek MM, Thornton AF, Delaney TF.

Radiother Oncol. 2006 Dec;81(3):243-9. Epub 2006 Oct 16.

PMID:
17050017
26.

Abnormal gene expression profiles in unaffected parents of patients with hereditary-type retinoblastoma.

Chuang EY, Chen X, Tsai MH, Yan H, Li CY, Mitchell JB, Nagasawa H, Wilson PF, Peng Y, Fitzek MM, Bedford JS, Little JB.

Cancer Res. 2006 Apr 1;66(7):3428-33.

27.
28.

Correlation of FDG-PET interpretation with survival in a cohort of glioma patients.

Pardo FS, Aronen HJ, Fitzek M, Kennedy DN, Efird J, Rosen BR, Fischman AJ.

Anticancer Res. 2004 Jul-Aug;24(4):2359-65.

29.

Glial tumor grading and outcome prediction using dynamic spin-echo MR susceptibility mapping compared with conventional contrast-enhanced MR: confounding effect of elevated rCBV of oligodendrogliomas [corrected].

Lev MH, Ozsunar Y, Henson JW, Rasheed AA, Barest GD, Harsh GR 4th, Fitzek MM, Chiocca EA, Rabinov JD, Csavoy AN, Rosen BR, Hochberg FH, Schaefer PW, Gonzalez RG.

AJNR Am J Neuroradiol. 2004 Feb;25(2):214-21. Erratum in: AJNR Am J Neuroradiol. 2004 Mar;25(3):B1.

30.

Neuroendocrine tumors of the sinonasal tract. Results of a prospective study incorporating chemotherapy, surgery, and combined proton-photon radiotherapy.

Fitzek MM, Thornton AF, Varvares M, Ancukiewicz M, Mcintyre J, Adams J, Rosenthal S, Joseph M, Amrein P.

Cancer. 2002 May 15;94(10):2623-34.

31.

Unexpected sensitivity to radiation of fibroblasts from unaffected parents of children with hereditary retinoblastoma.

Fitzek MM, Dahlberg WK, Nagasawa H, Mukai S, Munzenrider JE, Little JB.

Int J Cancer. 2002 Jun 10;99(5):764-8.

32.

Dose-escalation with proton/photon irradiation for Daumas-Duport lower-grade glioma: results of an institutional phase I/II trial.

Fitzek MM, Thornton AF, Harsh G 4th, Rabinov JD, Munzenrider JE, Lev M, Ancukiewicz M, Bussiere M, Hedley-Whyte ET, Hochberg FH, Pardo FS.

Int J Radiat Oncol Biol Phys. 2001 Sep 1;51(1):131-7.

PMID:
11516862
33.

Fractionated, three-dimensional, planning-assisted proton-radiation therapy for orbital rhabdomyosarcoma: a novel technique.

Hug EB, Adams J, Fitzek M, De Vries A, Munzenrider JE.

Int J Radiat Oncol Biol Phys. 2000 Jul 1;47(4):979-84.

PMID:
10863068
34.

Chondrosarcoma of the base of the skull: a clinicopathologic study of 200 cases with emphasis on its distinction from chordoma.

Rosenberg AE, Nielsen GP, Keel SB, Renard LG, Fitzek MM, Munzenrider JE, Liebsch NJ.

Am J Surg Pathol. 1999 Nov;23(11):1370-8.

PMID:
10555005
35.

Accelerated fractionated proton/photon irradiation to 90 cobalt gray equivalent for glioblastoma multiforme: results of a phase II prospective trial.

Fitzek MM, Thornton AF, Rabinov JD, Lev MH, Pardo FS, Munzenrider JE, Okunieff P, Bussière M, Braun I, Hochberg FH, Hedley-Whyte ET, Liebsch NJ, Harsh GR 4th.

J Neurosurg. 1999 Aug;91(2):251-60.

PMID:
10433313
36.
37.

Clonal heterogeneity in delayed decrease of plating efficiency of irradiated HeLa cells.

Fitzek M, Trott KR.

Radiat Environ Biophys. 1993;32(1):33-9.

PMID:
8460213
38.

Serum markers for primary and recurrent breast cancer: BCM-EIA, CAM 26 and CAM 29.

Ricketts D, Hadcocks L, Fitzek M, Rawson NS, Colston K, Powles TJ, Gazet JC, Coombes RC.

Tumour Biol. 1992;13(4):207-16.

PMID:
1411139
39.

His+ reversions caused in Salmonella typhimurium by different types of ionizing radiation.

Roos H, Thomas WH, Fitzek M, Kellerer AM.

Radiat Res. 1988 Nov;116(2):292-304.

PMID:
2847224
40.

Vectors for efficient expression in mammalian fibroblastoid, myeloid and lymphoid cells via transfection or infection.

Artelt P, Morelle C, Ausmeier M, Fitzek M, Hauser H.

Gene. 1988 Sep 7;68(2):213-9.

PMID:
3220255
41.

[Lymphokine secretion by human peripheral T-lymphocytes after in vitro stimulation. An analysis of interleukin-2 forms by immunoblotting with monoclonal antibodies].

Fitzek M, Hauser H, Mohr H, Plessing A, Conradt HS.

Beitr Infusionther Klin Ernahr. 1987;18:279-81. German. No abstract available.

PMID:
3501951
42.

[Hodgkin's disease associated with generalized infection with Mycobacterium kansasii].

Fitzek M, Rühland D.

Prax Pneumol. 1972 Oct;26(10):543-7. German. No abstract available.

PMID:
4644017

Supplemental Content

Loading ...
Support Center